AKERO THERAPEUTICS INC (AKRO) Stock News
NASDAQ:AKRO - Nasdaq - US00973Y1082 - Common Stock - Currency: USD
AKRO Latest News, Press Relases and Analysis
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
Akero Therapeutics Stock Rallies To 3-Month High On Buyout Report; Retail Investors Turn Bullish
The company reportedly hired an investment bank to explore a possible sale.
Best Biotech Stocks to Buy in 2025
Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.
This Stock Just Doubled in 1 Day -- Is It Still a Buy?
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Phase 2b SYMMETRY study preliminary results showed statistically significant reversal of compensated cirrhosis (F4) due to MASH following 96 weeks of...
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Why Akero Therapeutics (AKRO) Is Among the Best Performing Healthcare Stocks to Buy Now
We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best performing healthcare stocks to buy now. Trump’s Healthcare Executive Order Brings a Win On April 15, CNBC reported that President Trump’s […]
3 Reasons Datadog Stock Is Still a Top Artificial Intelligence Buy Right Now
Datadog reported first-quarter earnings that exceeded Wall Street expectations. The company's new artificial intelligence-powered cloud monitoring and observability features are generating strong growth. Datadog's significant opportunity within the rapidly expanding cloud services market supports a bullish outlook for the stock.
Akero Therapeutics et HistoIndex présentent de nouvelles analyses de l’essai de phase IIb HARMONY lors de présentations orales et d’affiches lors du congrès 2025 de l’EASL
L’analyse des résultats de l’EFX au moyen de la pathologie numérique basée sur l’IA souligne le potentiel d’évaluation de la réponse histopathologique ...
Akero Therapeutics und HistoIndex präsentieren neue Analysen der Phase-IIb-Studie HARMONY in Vorträgen und Postern auf dem EASL-Kongress 2025
Die Analyse der Ergebnisse zu EFX mit KI-basierter digitaler Pathologie unterstreicht den potenziellen Wert bei der Bewertung des histopathologischen...
Akero Therapeutics präsentiert auf dem EASL-Kongress 2025 die Ergebnisse nach 96 Wochen der klinischen Phase-IIb-Studie SYMMETRY zu Efruxifermin bei Patienten mit kompensierter Zirrhose, die durch MASH verursacht wird, und zeigt eine Verbesserung der
SOUTH SAN FRANCISCO, Kalifornien, May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), ein in der klinischen Phase tätiges...
Akero Therapeutics présente les résultats de la 96e semaine de l’essai clinique de phase 2b SYMMETRY sur l’éfruxifermine chez des patients atteints de cirrhose compensée causée par une stéatohépatite associée à un dysfonctionnement métabolique (MASH),
SOUTH SAN FRANCISCO, État de Californie, 10 mai 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (NASDAQ : AKRO), une société en phase clinique...
Akero Therapeutics gibt Publikation von „Phase IIb SYMMETRY“-Studie im New England Journal of Medicine bekannt
Die Ergebnisse stützen den potenziellen Nutzen von Efruxifermin (EFX) für eine Fibrosebesserung unter Patienten mit kompensierter Zirrhose (F4-Fibrose)...
Akero Therapeutics annonce la publication de l’essai de phase 2b SYMMETRY dans le New England Journal of Medicine
Les résultats confirment le bénéfice potentiel de l’éfruxifermine (EFX) pour déclencher une amélioration de la fibrose chez les patients atteints de...
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing...
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to...
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing...
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing...
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
3 Mid-Caps Worth Watching Closely in March
Unlike their mega-cap counterparts, which tend to grind, mid-caps can soar or crash within days, driven by headlines and pure speculation.
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX)...
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing...